Crémieux
Crémieux
ADA-0,70 %
Eli Lilly just showed that you can lose tons of fat while barely losing any muscle using their activin type-II receptor inhibitor, bimagrumab. We are approaching a golden era of weight loss, where everyone can easily be muscular and skinny. Prepare for hordes of hot Americans.
Gallery 1
The semaglutide-only weight loss results also speak against the lie that GLP-1RAs cause excess lean mass loss, as the proportion lost was comparable to typical non-GLP-1RA weight loss. To learn more, check out the update I just made on this article:
Reporting on this result from the ADA 2025 conference:
Egan Peltan
Egan Peltan
Can less weight loss be better weight loss? This morning at ADA, Eli Lilly released data on the Believe Phase 2b study of Bimagrumab in combination with a GLP-1 (Semaglutide) The goal: lose only fat Approach: anorectic + anabolic
@subtlechemism Nope.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@cmoncanes There's never been good evidence for them. It just doesn't gomd up on closer inspection.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@AnnieTyzak Eye issues? Never supported with strong evidence.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@elonmusk And it seems like consumers will have options, too. Multiple other companies are close to their own versions of this product: We live in amazing times!
Crémieux
Crémieux
More companies are jumping in to improve GLP-1-driven weight loss. Scholar Rock is now reporting their own results from using combination tirzepatide and a myostatin inhibitor. At 24 weeks, their results are comparable to semaglutide at 26 weeks with Regeneron's inhibitor:
Gallery 1
@AZchilly Then I'd say you didn't read the article. Here's a helpful thread with human rather than non-human primate results.
Crémieux
Crémieux
More companies are jumping in to improve GLP-1-driven weight loss. Scholar Rock is now reporting their own results from using combination tirzepatide and a myostatin inhibitor. At 24 weeks, their results are comparable to semaglutide at 26 weeks with Regeneron's inhibitor:
Gallery 1
Obținut de latwitter
8,13 K
0
Conținutul de pe această pagină este furnizat de terți. Dacă nu se menționează altfel, OKX nu este autorul articolului citat și nu revendică niciun drept intelectual pentru materiale. Conținutul este furnizat doar pentru informare și nu reprezintă opinia OKX. Nu este furnizat pentru a fi o susținere de nicio natură și nu trebuie să fie considerat un sfat de investiție sau o solicitare de a cumpăra sau vinde active digitale. În măsura în care AI-ul de generare este utilizat pentru a furniza rezumate sau alte informații, astfel de conținut generat de AI poate să fie inexact sau neconsecvent. Citiți articolul asociat pentru mai multe detalii și informații. OKX nu răspunde pentru conținutul găzduit pe pagini terțe. Deținerile de active digitale, inclusiv criptomonedele stabile și NFT-urile, prezintă un grad ridicat de risc și pot fluctua semnificativ. Trebuie să analizați cu atenție dacă tranzacționarea sau deținerea de active digitale este adecvată pentru dumneavoastră prin prisma situației dumneavoastră financiare.